PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 14, 2026Blood Cancer Discovery0 citations

Genomic features do not account for differences in multiple myeloma risk by ancestry

View Full Paper
KMKylee MaclachlanMPMarios PapadimitriouPBPatrick Blaney

Key Points

  • The aim is to explore whether genetic differences contribute to observed racial disparities in multiple myeloma risk.
  • Combined whole-genome sequencing data with publicly available datasets (n=1,286)
  • Investigated germline and somatic genomic features related to multiple myeloma
  • Analyzed epidemiological data and mutational signatures for comparison between ancestry groups.
  • No significant differences in germline or somatic genomic features that affect multiple myeloma risk between AFR and EUR populations.
  • Observed differences in detectability and timing of APOBEC-associated mutations but no clear link to age at diagnosis.
  • Patients from both AFR and EUR groups show equivalent clinical outcomes with proper access to therapies.

Abstract

Abstract Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma (MM). To comprehensively investigate somatic drivers in relation to inherited genetics in MM, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing MM between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiological data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop MM at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Maclachlan et al. (2026) studied this question.

synapsesocial.com/papers/6a2e482cb1cc60ccdea8c6d3https://doi.org/10.1158/2643-3230.bcd-25-0259
Ask AI
Helpful
Bookmark
Share
View Full Paper